Joon Seok Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joon Seok Park has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Arlene H. Sharpe
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
24 shared publications - Gordon J. Freeman
Department of Medical Oncology, Dana-Farber Cancer Institute
23 shared publications - Jared H. Rowe
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
21 shared publications - Marcia C. Haigis
Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, USA
21 shared publications - Megan E. Fung
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
21 shared publications - Shakchhi Joshi
Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, USA
21 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (2) , 186-193
Training Tomorrow’s Leaders in Cancer Immunology
The transition from trainee to independent investigator is one of the most challenging and formative phases of a scientific career. It requires not only scientific expertise but also the skills to lead, mentor, manage, and communicate effectively. The Arthur and Sandra Irving Cancer Immunology Symposium serves as a platform for established investigators to mentor trainees and early-career faculty as they navigate this transition to independence. Through sharing personal experiences and lessons from their own careers, senior leaders provide guidance on the scientific, professional, and personal challenges that shape a successful career in cancer immunology—emphasizing how curiosity, persistence, and a translational mindset can make a lasting real-world impact. This commentary highlights key themes, including leadership, communication, recruitment, and fundraising. Altogether, these insightful thoughts provide a framework for the next generation of cancer immunologists as they establish their independent careers as future leaders in the field.
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (2) , 186-193
Training Tomorrow’s Leaders in Cancer Immunology
The transition from trainee to independent investigator is one of the most challenging and formative phases of a scientific career. It requires not only scientific expertise but also the skills to lead, mentor, manage, and communicate effectively. The Arthur and Sandra Irving Cancer Immunology Symposium serves as a platform for established investigators to mentor trainees and early-career faculty as they navigate this transition to independence. Through sharing personal experiences and lessons from their own careers, senior leaders provide guidance on the scientific, professional, and personal challenges that shape a successful career in cancer immunology—emphasizing how curiosity, persistence, and a translational mindset can make a lasting real-world impact. This commentary highlights key themes, including leadership, communication, recruitment, and fundraising. Altogether, these insightful thoughts provide a framework for the next generation of cancer immunologists as they establish their independent careers as future leaders in the field.